CADL
NASDAQ · Biotechnology
Candel Therapeutics Inc
$7.53
+1.06 (+16.38%)
Open$6.57
Previous Close$6.47
Day High$7.54
Day Low$6.55
52W High$7.99
52W Low$4.34
Volume—
Avg Volume1.73M
Market Cap570.59M
P/E Ratio—
EPS$-0.70
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+532.0% upside
Current
$7.53
$7.53
Target
$47.59
$47.59
$33.44
$47.59 avg
$47.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.25M | 41.90M | 41.45M |
| Net Income | -4,564,062 | -5,052,559 | -4,078,464 |
| Profit Margin | -10.1% | -12.1% | -9.8% |
| EBITDA | -6,328,796 | -6,835,485 | -6,691,447 |
| Free Cash Flow | -4,822,512 | -5,572,664 | -3,889,078 |
| Rev Growth | -8.7% | -6.2% | +3.8% |
| Debt/Equity | 0.84 | 0.77 | 1.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |